NOTE

🌱 created from: glofitamab

starglo

Glofitamab Meets Primary Endpoint of Overall Survival in Phase 3 STARGLO Study for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Information

• Design: Phase 3, open-label, randomized trial
• Number of patients: Not specified
• Patients characteristics: Patients with relapsed or refractory diffuse large B-cell lymphoma who had received at least 1 line of therapy and are not candidates for autologous stem cell transplant
• Agent: Glofitamab (Columvi; Genentech), a CD20xCD3 T-cell engaging bispecific antibody
• Treatment line: Second-line therapy or later
• Trial Name or NCT Number: STARGLO study (NCT04408638)

Results

• Primary endpoint: Overall survival (OS)
• OS: Met its primary endpoint of OS
• Secondary endpoints:
  • Progression-free survival (PFS)
  • Complete response rate
  • Objective response rate
  • Duration of objective response

Other findings

• Safety: The safety of the combination regimen was consistent with the known profiles of the individual medicines
• Combination therapy: Glofitamab is being investigated in combination with other drugs, such as polatuzumab vedotin (Polivy; Genentech), in earlier lines of treatment for patients with B-cell non-Hodgkin lymphomas and other blood cancers

Summary The phase 3 STARGLO study has met its primary endpoint of overall survival in patients with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for autologous stem cell transplant. Glofitamab, a CD20xCD3 T-cell engaging bispecific antibody, has demonstrated significant improvement in overall survival compared to the control arm. The study’s results suggest that glofitamab may provide a new treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma.